the potential benefi t for some patients with multidrug-resistant (MDR) tuberculosis. 3 We wish to address their concern regarding applicability in countries of the former Soviet Union. Interim data (1-year, relapse-free outcomes due in 2017) from our observational study of the shortened regimen in Karakalpakstan, Uzbekistan, 4 contributed to the meta-analysis on which WHO based their recommendations. The Ministry of Health of Karakalpakstan, in partnership with Médecins sans Frontières, chose to pilot the shortened regimen in parallel with the line-probe assay for second-line drugs. This decision was made on the basis of the challenges of maintaining quality patient-centred care when scaling up a 20-month regimen: successful outcomes dropped to 62%; and loss to follow-up increased to 20%.
5
When considering whether to incorporate some or all of the WHO recommendations, national programme managers must balance the benefit of reducing treatment duration for some patients against the extra resources required to identify them. While some settings have high levels of resistance, there remain patients within these contexts who are likely to benefi t from shorter regimens.
Keeping patients at the centre of these decisions is key. With global successful treatment outcomes of just 50% for MDR tuberculosis, 6 perhaps the focus should be on who might benefit from the shorter regimen rather than who might not.
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WHO recommendations for multidrug-resistant tuberculosis
Giovanni Sotgiu and colleagues 1 (June 18, p 2486) described the choices facing national tuberculosis programmes in implementing the 2016 WHO recommendations for drug-resistant tuberculosis. 2 However, they might be being unduly pessimistic about the shortened treatment regimen (9-12 months). Successful implementation of this regimen, in settings from Somalia to India, shows
